12 Health Care Stocks Moving In Tuesday's After-Market Session
NextCure Inc NXTC
$4.15
▼ -17.59%
($-0.89)
⬇️ Below Yest. Low
🔥 High Short Interest
🎈 Low Float
📅 Earnings This Week
Open
$4.91
Prev Close
$5.03
Day Range
$4.10 – $5.08
52W Range
$1.55 – $15.74
Market Cap
$16.87M
Beta
1.31
EPS (TTM)
$-18.75
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-05-09 |
| Shares Out. | 4,070,000 |
| Website | nextcure.com/ ↗ |
| Phone | 12403994900 |
| Employees | 40 |
| Net Income | -$9.8M |
| Total Assets | $38.0M |
| Total Liabilities | $11.3M |
| Equity | $26.7M |
About NextCure Inc
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
NextCure Inc is a publicly traded company under the ticker symbol NXTC on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)